COVID-19
Biosimilars
Cataract Therapeutics
DME
Gene Therapy
Workplace
Ptosis
Optic Relief
Imaging
Geographic Atrophy
AMD
Presbyopia
Ocular Surface Disease
Practice Management
Pediatrics
Surgery
Therapeutics
Optometry
Retina
Cataract
Pharmacy
IOL
Dry Eye
Understanding Antibiotic Resistance
Refractive
Cornea
Glaucoma
OCT
Ocular Allergy
Clinical Diagnosis
Technology

Dexamethasone intracameral drug-delivery suspension in vitreoretinal surgery inflammation (ASRS 2020)

Name: Dexamethasone intracameral drug-delivery suspension in vitreoretinal surgery inflammation (ASRS 2020)
Uploaded: 2020-08-03T04:00:00.000Z
Description: Daniel F. Kiernan, MD, FACS, speaks on the key findings and take-aways of his presentation "Dexamethasone intracameral drug-delivery suspension for inflammation associated with vitreoretinal surgery."

August 3, 2020

Alex Delaney-Gesing
David Hutton

Video

Conferences|ASRS

Daniel F. Kiernan, MD, FACS, speaks on the key findings and take-aways of his presentation "Dexamethasone intracameral drug-delivery suspension for inflammation associated with vitreoretinal surgery."

Daniel F. Kiernan, MD, FACS, speaks with Ophthalmology Times®' David Hutton on the key findings and take-aways from his presentation, "Dexamethasone intracameral drug-delivery suspension for inflammation associated with vitreoretinal surgery," during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.

See more ASRS meeting coverage here